Phase II study of 13-cis-retinoic acid in pediatric patients with acute nonlymphocytic leukemia--a Pediatric Oncology Group study.
Forty-one patients with refractory acute non-lymphocytic leukemia (ANLL) in relapse were treated with 13-cis-retinoic acid (cRA) as salvage therapy. The cRA was given as a single oral dose of 100 mg/m2/day for 4 weeks. One patient achieved a complete remission and two patients achieved a partial remission with reduction of the bone marrow blast count from 40 to 20% after the first course. We recommend further study of cRA in combination with other agents in the treatment of ANLL in children.
Bell
B A
BA
Division of Pediatric Hematology/Oncology, Emory University, Atlanta, Georgia 30322.
Findley
H W
HW
Krischer
J
J
Whitehead
V M
VM
Holbrook
T
T
Haggard
M E
ME
Konrad
P N
PN
Hensley
M
M
Ragab
A H
AH
D000293:Adolescent; D002455:Cell Division; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D015474:Isotretinoin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007947:Leukemia, Megakaryoblastic, Acute / Q000188:drug therapy / Q000473:pathology; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy / Q000473:pathology; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy / Q000473:pathology; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000473:pathology; D008297:Male; D012074:Remission Induction; D014407:Tumor Cells, Cultured
D015474:Isotretinoin